Le Lézard
Classified in: Health
Subject: ACC

Bulletin from the Annual General Meeting of Alfa Laval AB (publ)


LUND, Sweden, April 25, 2023 /PRNewswire/ -- The Annual General Meeting of Alfa Laval AB (publ) was held on Tuesday, April 25, 2023, at Scandic Star Hotel in Lund. The Annual General Meeting was held under the chairmanship of Alfa Laval's Chairman of the Board Dennis Jönsson and the company's President and CEO Tom Erixon gave a presentation about the past year and the strategic direction ahead.

In his presentation, Tom Erixon talked about 2022 ? a year characterized by both challenges but also record high invoicing and order intake driven by a strong demand for more sustainable solutions in all of Alfa Laval's three divisions. The presentation also elaborated on the importance of continuing to invest for the future by increased investments in R&D, new competences and production capacity to lead the development in the company's technology areas and support both Alfa Laval and the company's customers in the work to reduce climate impact.

Income statement and balance sheet and discharge from liability

The Annual General Meeting approved the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet for 2022 as presented. The members of the Board of Directors and the company's CEO were discharged from liability for the period covered by the annual report.

Dividend

The Annual General Meeting resolved on a dividend to shareholders of SEK 6.00 per share. It was further resolved that the record date for the dividend should be Thursday, April 27, 2023, which means that payment of the dividend is expected to be distributed by Euroclear Sweden AB on Wednesday, May 3, 2023.

Board of Directors and External Auditor

The Annual General Meeting resolved that the number of Board members appointed by the Meeting shall be nine, with no deputies. Both the number of auditors and deputy auditors were decided to be two.

In accordance with the Nomination Committee's proposal, Dennis Jönsson, Finn Rausing, Henrik Lange, Jörn Rausing, Lilian Fossum Biner, Ray Mauritsson and Ulf Wiinberg were re-elected and Anna Müller and Nadine Crauwels was newly elected as members of the Board of Directors for the period until the end of the 2024 Annual General Meeting. Dennis Jönsson was re-elected as Chairman of the Board of Directors.

The Annual General Meeting resolved to re-elect the authorized public accountant Karoline Tedevall and the authorized public accountant Andreas Troberg was newly elected as the company's auditors and the authorized public accountants Henrik Jonzén and Andreas Mast as the company's deputy auditors for the forthcoming year.

Fees and compensation

The Annual General Meeting resolved, in accordance with the Nomination Committee's proposal, that board fees shall be paid in the amount of SEK 1,950,000 to the Chairman of the Board and SEK 650,000 each to other members who are not employees of the company. Furthermore, fees for committee work shall be paid in the amount of SEK 300,000 to the Chairman of the Audit Committee and in the amount of SEK 150,000 each to other members, and in the amount of SEK 75,000 to the Chairman of the Remuneration Committee and SEK 75,000 each to the other members.

It was decided, in accordance with the Nomination Committee's proposal, that auditors' fees shall be paid in accordance with approved invoices.

The Annual General Meeting resolved, in accordance with the Board's proposal, to amend the guidelines for remuneration to senior executives adopted at the 2021 Annual General Meeting.

The Annual General Meeting also resolved to approve the remuneration report presented by the Board.

Reduction of the share capital

The Annual General Meeting resolved to reduce the share capital, for the provision of unrestricted equity, by cancelling the 550,508 own shares held by Alfa Laval AB, whereby the share capital is reduced by SEK 1,485,377.34.

To restore the share capital after the reduction of the share capital, the Board of Directors proposed that the Annual General Meeting simultaneously resolves to increase the share capital by SEK 1,485,377.34 by way of a bonus issue without issuing new shares. The reduction amount is proposed to be transferred from the company's non-restricted equity.

Complete minutes from the Annual General Meeting will be published on www.alfalaval.com.

For more information please contact:
Johan Lundin
Head of Investor Relations
Tel: +46 46 36 65 10
Mobile: +46 730 46 30 90

The following files are available for download:

https://mb.cision.com/Main/905/3757318/2008344.pdf

AGM bulletin 2023

SOURCE Alfa Laval


These press releases may also interest you

at 07:40
The "Global Enzyme Contract Manufacturing Market (2024 Edition): Analysis By Source (Plant, Animal, Microbe), By Application, By End-Use, By Region: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering....

at 07:30
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to participate in...

at 07:30
Shoulder Innovations, a leader in the shoulder replacement implant market, is proud to announce the launch of its latest product: the InSettm 95 Humeral Stem. This product is designed to enhance surgical outcomes and improve patient recovery for...

at 07:15
mBIOTA Labs, a medical food company revolutionizing oral nutrition through their proprietary palatable elemental diet, mBIOTA Elementaltm, today announced the initial study results of their first prospective clinical trial assessing the efficacy of...

at 07:15
Epicutis®, a professional, medical-grade luxury skincare line by Signum Biosciences, is thrilled to announce its partnership with the Four Seasons Hotel Toronto along with new Epicutis® Lipid Recovery Mask for Eyes, developed in collaboration with...

at 07:05
Beaconcure Inc., a leader in AI-enabled clinical data validation and automation, announces a strategic partnership with Phastar Inc., a global specialist biometrics contract research organization (CRO), to enhance clinical review processes in...



News published on and distributed by: